Matches in SemOpenAlex for { <https://semopenalex.org/work/W82585863> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W82585863 abstract "Background : Activated factor XIII (FXIIIa) is a blood transglutaminase that mediates fibrinolytic resistance and is a hallmark of acute thrombi. Noninvasive molecular imaging of FXIIIa may offer a novel approach to identify acute thrombi and to gauge fibrinolytic resistance in vivo. Here we developed and validated a FXIIIa thrombosis imaging strategy using noninvasive integrated SPECT/CT. Methods: A FXIIIa-targeted peptide agent (F13) was synthesized using NQEQVSPLTLLK chelated to DOTA and then labeled with 111 InCl 3 . A control agent (C13, 111 In-NAEQVSPLTLLK) was analogously synthesized. In vitro validation of the F13 agent was performed in human plasma clots. Next, the in vivo blood-half life of F13 was determined in mice (n=4). In vivo thrombosis studies (n=15 mice) were then performed using 10% ferric chloride jugular venous thrombi aged 1 hour or 16 hours. Mice were intravenously injected with 200 μCi of F13 or C13. After 4 hours, mice underwent integrated CT angiography (72 μm isotropic resolution) and SPECT imaging (32 minute acquisition). In situ thrombi were then resected for radioactivity and weight measurements. Results : Human plasma clots incubated with F13 showed 280–740% greater counts per minute (CPM) than controls (p<0.01). F13 binding was dose-dependent and >90% inhibited by pretreatment with iodoacetamide, an alkylating agent. The blood half-life of F13 was calculated to be 16 minutes. In one hour thrombi, in vivo SPECT/CT imaging revealed strong focal F13 SPECT signal in the co-registered ipsilateral venous thrombi but not the contralateral normal jugular vein. One hour thrombi in the F13 group had 15-fold greater radioactivity than the C13 group (4.6±3.6% vs. 0.3±0.2% injected dose per gram tissue, IDGT, p<0.01). Compared to 1 hour thrombi, 16 hour old thrombi had 4-fold less F13 radioactivity (1.1%±0.1% IDGT, p<0.05). Conclusions : Blood transglutaminase FXIIIa can be noninvasively detected using a FXIIIa-sensitive and specific imaging agent for integrated SPECT/CT. The current in vivo results further validate that activated factor XIII is a hallmark of acute thrombi and declines in activity over time. This clinically translatable imaging strategy could permit visualization of FXIIIa in patients with thrombotic syndromes." @default.
- W82585863 created "2016-06-24" @default.
- W82585863 creator A5010159755 @default.
- W82585863 creator A5015835766 @default.
- W82585863 creator A5035255903 @default.
- W82585863 creator A5049584767 @default.
- W82585863 creator A5067255019 @default.
- W82585863 creator A5070638440 @default.
- W82585863 creator A5078805078 @default.
- W82585863 creator A5085964606 @default.
- W82585863 date "2007-10-16" @default.
- W82585863 modified "2023-10-16" @default.
- W82585863 title "Abstract 804: Noninvasive Integrated SPECT/CT Molecular Imaging of Activated Factor XIII Activity in Thrombosis" @default.
- W82585863 doi "https://doi.org/10.1161/circ.116.suppl_16.ii_155-b" @default.
- W82585863 hasPublicationYear "2007" @default.
- W82585863 type Work @default.
- W82585863 sameAs 82585863 @default.
- W82585863 citedByCount "0" @default.
- W82585863 crossrefType "journal-article" @default.
- W82585863 hasAuthorship W82585863A5010159755 @default.
- W82585863 hasAuthorship W82585863A5015835766 @default.
- W82585863 hasAuthorship W82585863A5035255903 @default.
- W82585863 hasAuthorship W82585863A5049584767 @default.
- W82585863 hasAuthorship W82585863A5067255019 @default.
- W82585863 hasAuthorship W82585863A5070638440 @default.
- W82585863 hasAuthorship W82585863A5078805078 @default.
- W82585863 hasAuthorship W82585863A5085964606 @default.
- W82585863 hasConcept C126322002 @default.
- W82585863 hasConcept C150903083 @default.
- W82585863 hasConcept C207001950 @default.
- W82585863 hasConcept C2780011451 @default.
- W82585863 hasConcept C2780868729 @default.
- W82585863 hasConcept C2984398910 @default.
- W82585863 hasConcept C2989005 @default.
- W82585863 hasConcept C71924100 @default.
- W82585863 hasConcept C86803240 @default.
- W82585863 hasConceptScore W82585863C126322002 @default.
- W82585863 hasConceptScore W82585863C150903083 @default.
- W82585863 hasConceptScore W82585863C207001950 @default.
- W82585863 hasConceptScore W82585863C2780011451 @default.
- W82585863 hasConceptScore W82585863C2780868729 @default.
- W82585863 hasConceptScore W82585863C2984398910 @default.
- W82585863 hasConceptScore W82585863C2989005 @default.
- W82585863 hasConceptScore W82585863C71924100 @default.
- W82585863 hasConceptScore W82585863C86803240 @default.
- W82585863 hasIssue "suppl_16" @default.
- W82585863 hasLocation W825858631 @default.
- W82585863 hasOpenAccess W82585863 @default.
- W82585863 hasPrimaryLocation W825858631 @default.
- W82585863 hasRelatedWork W2066061284 @default.
- W82585863 hasRelatedWork W2085148854 @default.
- W82585863 hasRelatedWork W2091748901 @default.
- W82585863 hasRelatedWork W2382040801 @default.
- W82585863 hasRelatedWork W2388756376 @default.
- W82585863 hasRelatedWork W2899086445 @default.
- W82585863 hasRelatedWork W2981730791 @default.
- W82585863 hasRelatedWork W3018641166 @default.
- W82585863 hasRelatedWork W4245827464 @default.
- W82585863 hasRelatedWork W1603374058 @default.
- W82585863 hasVolume "116" @default.
- W82585863 isParatext "false" @default.
- W82585863 isRetracted "false" @default.
- W82585863 magId "82585863" @default.
- W82585863 workType "article" @default.